Profil

Gennigens Christine

Département des sciences cliniques

See author's contact details
ORCID
0000-0003-4526-6219
Main Referenced Co-authors
Jerusalem, Guy  (31)
Kridelka, Frédéric  (25)
De Cuypere, Marjolein  (23)
Gonne, Elodie  (19)
Goffin, Frédéric  (17)
Main Referenced Keywords
oncology (21); Humans (13); Oncology (8); Female (7); chemotherapy (4);
Main Referenced Disciplines
Oncology (96)
Hematology (6)
Surgery (4)
Endocrinology, metabolism & nutrition (3)
Radiology, nuclear medicine & imaging (3)

Publications (total 110)

The most downloaded
19151 downloads
Freres, P., Collignon, J., Gennigens, C., Scagnol, I., Rorive, A., Barbeaux, A., Coucke, P., & Jerusalem, G. (March 2010). Le cancer du sein "triple négatif". Revue Médicale de Liège, 65 (3), 120-126. https://hdl.handle.net/2268/73651

The most cited

1649 citations (Scopus®)

van der Graaf, W., Blay, J., Chawla, S., Kim, D., Bui-Nguyen, B., Casali, P., Schöffski, P., Aglietta, M., Staddon, A., Beppu, Y., Le Cesne, A., Gelderblom, H., Judson, I., Araki, N., Ouali, M., Marreaud, S., Hodge, R., Dewji, M., Coens, C., ... GENNIGENS, C. (19 May 2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 379 (9829), 1879-1886. doi:10.1016/S0140-6736(12)60651-5 https://hdl.handle.net/2268/186327

Manso, L., Vergote, I., Fujiwara, K., Angelergues, A., Zikan, M., Jordan, S., Lee, J.-Y., Barraclough, L., Maluf, F. C., Lorusso, D., Yonemori, K., Gennigens, C., Gonzalez Martin, A., Heitz, F., Westermann, A. M., Covens, A., Whalley, E., Chen, Y., Soumaoro, I., & Randall, L. M. (01 June 2024). Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301. Journal of Clinical Oncology, 42 (16_suppl), 5531-5531. doi:10.1200/jco.2024.42.16_suppl.5531
Peer Reviewed verified by ORBi

Berton, D., Pautier, P., Lorusso, D., Gennigens, C., Gladieff, L., Kryzhanivska, A., Bowman, J., Tian, C., Cornfeld, M., & Van Gorp, T. (01 June 2024). Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study. Gynecologic Oncology, 186, 191 - 198. doi:10.1016/j.ygyno.2024.05.025
Peer Reviewed verified by ORBi

Gennigens, C., Altintas, S., Baurain, J.-F., Denys, H., Henry, S., Vergote, I., & Van Gorp, T. (March 2024). Immunotherapy for advanced endometrial carcinoma: Time for a paradigm shift? Belgian Journal of Medical Oncology, 18 (2), 49-59.
Peer Reviewed verified by ORBi

Motzer, R. J., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Alekseev, B., Rha, S. Y., Merchan, J., Goh, J. C., Lalani, A.-K. A., De Giorgi, U., Melichar, B., Hong, S.-H., Gurney, H., Méndez-Vidal, M. J., Kopyltsov, E., Tjulandin, S., Gordoa, T. A., ... Gennigens, C. (Other coll.). (2024). Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology, 2301569. doi:10.1200/JCO.23.01569
Peer Reviewed verified by ORBi

Martínez, A. G., Martin-Calvo, N., Meydanli, M. M., Khatib, G., Kaidarova, D., Ayhan, A., Borella, F., Sanchez-Salcedo, M., Sanci, M., Chaves, C. B. B. P., Elsersy, M. A. M., Bolatbekova, R., Vorias, G., Gil-Moreno, A., Perrone, A. M., Mishra, J., Zusterzeel, P., Theodoulidis, V., Aluloski, I., ... De Agustin, L. C. (2024). #819 Primary results of DAYDREAM study, a real-world multicentre study on the efficacy of adjuvant chemotherapy in high-grade uterine sarcomas. International Journal of Gynecological Cancer, 34, 573.
Peer Reviewed verified by ORBi

Streel, S., Kirkove, D., Seidel, L., Rorive, A., Freres, P., Gennigens, C., Sibille, A., PAULUS, A., Gagnayre, R., Pétré, B., & Jerusalem, G. (2024). Beyond Information: Revealing Alarming Decision-Making Results in Coping with Immune-Related Adverse Events through Hypothetical Scenarios An illustration through the Immuno’Act© acceptance study. Belgian Journal of Medical Oncology, 24-25.
Peer Reviewed verified by ORBi

Baccus, L., Dheur, A., Salmon, A., Delbecque, K., Goffin, F., De Cuypere, M., PLEYERS, C., Lovinfosse, P., Danthine, D., THILLE, A., Gonne, E., Gennigens, C., Kridelka, F., & Kakkos, A. (2024). 414 Potential association between quantified LVSI status and molecular profile in predicting nodal metastases for patient suffering early-stage endometrial cancer. International Journal of Gynecological Cancer, 34, 177-A178.
Peer Reviewed verified by ORBi

Streel, S., Kirkove, D., Gagnayre, R., Rorive, A., Freres, P., Gennigens, C., UCCELLO, S., Evrard, V., Greco, V., CAMPOS CORRAL, I., Seidel, L., Sibille, A., PAULUS, A., Pétré, B., & Jerusalem, G. (2024). Vers l’intégration de l'outil « Immuno’Act© » à l'éducation des patients oncologiques sous immunothérapie : Évaluation préliminaire de l'acceptation, du sentiment d'auto-efficacité et de la prise de décision [Poster presentation]. 10ème Congrès de la Société d'Education Thérapeutique Européenne, Liège, Belgium.
Peer reviewed

Wick, M., Sautois, B., Freres, P., Denis, C., Seidel, L., Waltregny, D., & Gennigens, C. (2024). Metastatic reanl cell carcinoma : monocentric retrospective data on first-line treatment. Belgian Journal of Medical Oncology.
Peer Reviewed verified by ORBi

Gilon, M., Josse, C., Boulet, D., Bours, V., Waltregny, D., Jerusalem, G., & Gennigens, C. (2024). Role of eosinophils in clear-cell renal cell carcinoma. Belgian Journal of Medical Oncology.
Peer Reviewed verified by ORBi

Grisham, R., Aghajanian, C., Nieuwenhuysen, E. V., Rodrigues, M., Ring, K., Santin, A., Colombo, N., Prendergast, E., Thaker, P., Moore, K., Salinas, E., Ray-Coquard, I., Chon, H. S., Rose, P., Oaknin, A., Clamp, A., Gandhi, M., Monk, B., Holloway, R., ... Banerjee, S. (2023). PO004LBA/#1515  Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy. International Journal of Gynecological Cancer. doi:10.1136/ijgc-2023-igcs.4
Peer reviewed

Morfouace, M., Oliveira, J., Penel, N., Peron, J., Pracht, M., Brasiuniene, B., Capela Marques, A., Gennigens, C., Greillier, L., Robert, M.-S., Klumpen, H. J., Peeters, R., Licitra, L. F. L., Girard, N., Gietema, J. A., de Herder, W., Kapiteijn, E., Idbaih, A., Ray-Coquard, I. L., & Blay, J.-Y. (October 2023). 132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study. Annals of Oncology, 34, 233-S234. doi:10.1016/j.annonc.2023.09.2857
Peer Reviewed verified by ORBi

Banerjee, S. N., Ring, K. L., Niewenhuysen, E. V., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A. D., Clamp, A. R., Moore, K. N., Rose, P. G., David M, O. M., Chon, H. S., Salinas, E. A., Prendergast, E. N., Lustgarten, S., Rodrigues, M., Gennigens, C., Monk, B. J., & Grisham, R. N. (September 2023). #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). International Journal of Gynecological Cancer, 33, 20-A21. doi:10.1136/ijgc-2023-esgo.29
Peer reviewed

DEMARTEAU, C., PLEYERS, C., HERMESSE, J., Gennigens, C., Kakkos, A., Gonne, E., Goffin, F., & Kridelka, F. (September 2023). #749 Optimizing brachytherapy applicators implantation in locally advanced cervical cancer with transrectal ultrasound guidance. International Journal of Gynecological Cancer, 33, 91-A92. doi:10.1136/ijgc-2023-esgo.183
Peer reviewed

Vergote, I., Van Nieuwenhuysen, E., O'Cearbhaill, R. E., Westermann, A., Lorusso, D., Ghamande, S., Collins, D. C., Banerjee, S., Mathews, C. A., Gennigens, C., Cibula, D., Tewari, K. S., Madsen, K., Köse, F., Jackson, A. L., Boere, I. A., Scambia, G., Randall, L. M., Sadozye, A., ... Monk, B. J. (2023). Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Journal of Clinical Oncology, 2300720. doi:10.1200/JCO.23.00720
Peer Reviewed verified by ORBi

Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, E. I., Guerra-Alia, E., Zola, P., Wimberger, P., Debruyne, P. R., Falcó, E., Ferrero, A., Muallem, M. Z., Kerger, J., García-Martinez, E., Pignata, S., Sehouli, J., Van Gorp, T., Gennigens, C., & Rubio, M. J. (July 2023). Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. Gynecologic Oncology, 174, 80 - 88. doi:10.1016/j.ygyno.2023.04.028
Peer Reviewed verified by ORBi

Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., Hanker, L. C., Stuckey, A., Boere, I., Gold, M. A., Auranen, A., Pothuri, B., Cibula, D., McCourt, C., Raspagliesi, F., ... Gennigens, C. (Other coll.). (08 June 2023). Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine, 388 (23), 2145 - 2158. doi:10.1056/NEJMoa2216334
Peer Reviewed verified by ORBi

Banerjee, S. N., Ring, K. L., Van Nieuwenhuysen, E., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A., Clamp, A. R., Moore, K. N., Rose, P. G., O'Malley, D. M., Chon, H. S., Salinas, E. A., Prendergast, E. N., Lustgarten, S., Rodrigues, M., Gennigens, C., Monk, B. J., & Grisham, R. N. (01 June 2023). Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Journal of Clinical Oncology, 41 (16_suppl), 5515-5515. doi:10.1200/jco.2023.41.16_suppl.5515
Peer Reviewed verified by ORBi

Verbiest, A., Baldewijns, M., Beuselinck, B., Debruyne, P., Gennigens, C., Pelgrims, G., Roumeguère, T., Seront, E., Sundahl, N., & Rottey, S. (June 2023). Update on the management of renal cell carcinoma: The BSMO expert panel recommendations. Belgian Journal of Medical Oncology, 17 (4), 118-127.
Peer Reviewed verified by ORBi

Boere, I., Vergote, I., Hanssen, R., Jalving, M., Gennigens, C., Ottevanger, P., van de Wouw, Y. J., Rijcken, C. J. F., Mathijssen, R. H. J., & Ledermann, J. (2023). CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer. International Journal of Gynecological Cancer, 2023-004308. doi:10.1136/ijgc-2023-004308
Peer Reviewed verified by ORBi

Lucia, F., Bourbonne, V., PLEYERS, C., Dupré, P.-F., Miranda, O., Visvikis, D., Pradier, O., Abgral, R., Mervoyer, A., Classe, J.-M., Rousseau, C., Vos, W., HERMESSE, J., Gennigens, C., De Cuypere, M., Kridelka, F., Schick, U., Hatt, M., Hustinx, R., & Lovinfosse, P. (2023). Multicentric development and evaluation of 18F-FDG PET/CT and MRI radiomics models to predict para-aortic lymph node involvement in locally advanced cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging. doi:10.1007/s00259-023-06180-w
Peer Reviewed verified by ORBi

Streel, S.* , Salmon, A.* , DHEUR, A., Bours, V., LEROI, N., Habran, L., Delbecque, K., Goffin, F., PLEYERS, C., Kakkos, A., Gonne, E., Seidel, L., Kridelka, F.* , & Gennigens, C.*. (02 March 2023). Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer. International Journal of Molecular Sciences, 24 (5), 4866. doi:10.3390/ijms24054866
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Gennigens, C., Denys, H., Altintas, S., Kerger, J., Baurain, J.-F., Bours, V., Henry, S., Van De Vijver, K., Lambrechts, D., & Vergote, I. (March 2023). Value of testing for homologous recombination repair deficiency in newly diagnosed advanced-stage epithelial ovarian cancer: Recommendations for Belgian physicians. Belgian Journal of Medical Oncology, 17 (2), 38-45.
Peer Reviewed verified by ORBi

DHEUR, A., Salmon, A., Streel, S., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kridelka, F., Kakkos, A., & Gennigens, C. (February 2023). p53 status : a strong negative prognostic factor in endometrial carcinoma [Poster presentation]. 25th BSMO Annual Meeting 2023, Hasselt, Belgium.
Peer reviewed

Salmon, A., Streel, S., DHEUR, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kakkos, A., Kridelka, F., & Gennigens, C. (February 2023). Agreement between immunohistochemistry and molecular techniques to assess microsatellite instability and p53 status in endometrial cancer [Poster presentation]. 25th BSMO Annual Meeting 2023, Hasselt, Belgium.
Peer reviewed

Kuchimanchi, M., Koliadi, A., Pothuri, B., Alskär, O., Krivak, T., Pishchyk, M., Hanze, E., Zajic, S., Segev, Y., Backes, F. J., Gennigens, C., Bouberhan, S., Buscema, J., Melhem, M., & Shahin, M. S. (2023). Exposure-Response Analysis of Dostarlimab in Combination with Platinum-Containing Chemotherapy in Primary Advanced or Recurrent Endometrial Cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial [Poster presentation]. American Conference on Pharmacometrics (ACoP), Maryland, United States.
Peer reviewed

Gennigens, C., Enguita, A., & Feys, T. (2023). Highlights in gynaecological cancer. Belgian Journal of Medical Oncology, 17 (8), 298-303.
Peer Reviewed verified by ORBi

HERMESSE, J., PLEYERS, C., Gennigens, C., De Cuypere, M., Lovinfosse, P., Seidel, L., Coucke, P., & Kridelka, F. (2023). Outcome analysis of HDR compared to PDR IGABT in locally advanced cervical cancer: a single-center cohort analysis. Strahlentherapie und Onkologie. doi:10.1007/s00066-022-01982-7
Peer Reviewed verified by ORBi

Verdonck Beatove, E., Piette, C., Sautois, B., & Gennigens, C. (2023). Late metastatic relapse of an initially bifocal intracranial germ cell tumor with modestly elevated tumor markers: A case report [Poster presentation]. 25th BSMO Annual Meeting 2023, Hasselt, Belgium.
Peer reviewed

Berton-Rigaud, D., Pautier, P., Lorusso, D., Gennigens, C., Gladieff, L., Kryzhanivska, A., Bowman, J., Tian, C., Cornfeld, M., & Van Gorp, T. (2023). Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H) [Poster presentation]. European Society for Medical Oncology Congress, Madrid, Spain.
Peer reviewed

Gennigens, C. (2023). ADVANCED CERVICAL CANCER: CURRENT TREATMENTS AND FUTURE STRATEGIES. Belgian Journal of Medical Oncology.
Peer Reviewed verified by ORBi

Hennuy, C., Defrère, P., MAWEJA, S., Thiry, A., & Gennigens, C. (November 2022). Bilateral breast desmoid - type fibromatosis, case report and literature review. Gland Surgery, 11 (11), 1832-1841. doi:10.21037/gs-22-271
Peer Reviewed verified by ORBi

Dheur, A., Bours, V., De Cuypere, M., Delbecque, K., Gennigens, C., Goffin, F., Gonne, E., HERMESSE, J., Kridelka, F., Lovinfosse, P., PLEYERS, C., Salmon, A., & Kakkos, A. (October 2022). 2022-RA-193-ESGO Cost-effectiveness of molecular profiling for endometrial neoplasia: a single institution experience [Poster presentation]. 23rd European Congress on Gynaecological Oncology. doi:10.1136/ijgc-2022-esgo.203
Peer reviewed

Salmon, A., Dheur, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kridelka, F., Kakkos, A., & Gennigens, C. (October 2022). Endometrial cancer: lymphovascular space invasion is a negative prognostic factor [Poster presentation]. 23rd European Congress on Gynaecological Oncology. doi:10.1136/ijgc-2022-esgo.264
Peer reviewed

DHEUR, A., Bours, V., De Cuypere, M., Delbecque, K., Gennigens, C., Goffin, F., Gonne, E., HERMESSE, J., Kakkos, A., Lovinfosse, P., PLEYERS, C., Salmon, A., & Kridelka, F. (29 September 2022). Defining prognostic risk groups amongst patients with endometrial cancer:respective role of 2009 figo stage and molecular profile [Poster presentation]. IGCS 2022, New York, United States.
Peer reviewed

Salmon, A., DHEUR, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., De Cuypere, M., Goffin, F., Lovinfosse, P., Kakkos, A., Kridelka, F., & Gennigens, C. (29 September 2022). Endometrial cancer: agreement between P53 immunohistochemistry and TP53 mutational analysis ? [Poster presentation]. IGCS 2022, New York, United States.
Peer reviewed

Gennigens, C., Jerusalem, G., LAPAILLE, L., De Cuypere, M., Streel, S., Kridelka, F., & Ray-Coquard, I. (09 September 2022). Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open, 7 (5), 1-3. doi:10.1016/j.esmoop.2022.100579
Peer Reviewed verified by ORBi

De Cuypere, M., PLEYERS, C., HERMESSE, J., Lovinfosse, P., Delbecque, K., Gonne, E., Kakkos, A., Goffin, F., Kridelka, F., & Gennigens, C. (2022). A comparison of survival and recurrence pattern of patients presenting locally advanced cervical cancer according to the histological subtype: a monocentric retrospective study [Poster presentation]. 23rd European Congress on Gynecological Oncology, Berlin, Germany.
Peer reviewed

Vergote, I., Van Nieuwenhuysen, E., De Waele, S., Vulsteke, C., Lamot, C., Van den Bulck, H., Claes, N., Graas, M.-P., Delbrock, G., Spoormans, I., Vuylsteke, P., Honhon, B., Verhoeven, D., De Maeseneer, D., Dirix, L., Mebis, J., Vroman, P., Denys, H., Martinez Mena, C., ... GENNIGENS, C. (2022). Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer : a study of the Belgian and Luxembourg Gynaecological Oncology Group. International Journal of Gynecological Cancer, 1-8. doi:10.1136/ijgc-2021-003190
Peer Reviewed verified by ORBi

Mettlen, C., Gennigens, C., & Kurth, W. (2022). L’image du mois. Descellement aseptique d’une méga-prothèse de genou. Revue Médicale de Liège, 77 (1), 5-7.
Peer reviewed

I. Vergote, H. Denys, S. Altintas, J. Kerger, J-F. Baurain, Bours, V., S. Henry, K. Van de Vijver, D. Lambrechts, & Gennigens, C. (2022). Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer:A Belgian expert opinion. Facts, Views and Vision in Obgyn, 14 (2), 111-120.
Peer Reviewed verified by ORBi

Lamarca, A., Morfouace, M., Tejpar, S., Oliveira, J., Capela, A., Penel, N., Gennigens, C., Brasiuniene, B., Peron, J., Stevovic, A., Blay, J.-Y., & Klümpen, H.-J. (2022). Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few. Annals of Oncology. doi:10.1016/j.annonc.2022.07.006
Peer Reviewed verified by ORBi

Gennigens, C., DHEUR, A., Bours, V., Delbecque, K., Gonne, E., PLEYERS, C., Seidel, L., Streel, S., De Cuypere, M., Goffin, F., Lovinfosse, P., Kakkos, A., Kridelka, F., & Salmon, A. (2022). 2022-RA-967-ESGO Endometrial cancer: agreement between microsatellite instability in immunohistochemistry and molecular analysis ? International Journal of Gynecological Cancer. doi:10.1136/ijgc-2022-ESGO.266
Peer Reviewed verified by ORBi

Berton, D., Pautier, P., Lorusso, D., GENNIGENS, C., Gladieff, L., Kryzhanivska, A., Ranganathan, S., Tian, C., Bourayou, N., & Vergote, I. (10 November 2021). Retifanlimab (INCMGA00012) in Patients With Recurrent MSI-H or dMMR Endometrial Cancer: Results From the POD1UM-101 Study [Poster presentation]. Society for Immunotherapy of Cancer's 36th Annual Meeting, Wasthington, United States - District of Columbia.

ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571
Peer reviewed

Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, I., Guerra-Alia, E., Zola, P., Wimberger, P., Debruyne, P., Falco, E., Ferrero, A., Muallem, M., Kerger, J., Garcia Martinez, E., Pignata, S., Sehouli, J., Van Gorp, T., GENNIGENS, C., & Rubio Pérez, M. (12 October 2021). Randomised phase II BGOG/ENGOT-CX1 study of Paclitaxel-Carboplatin with or without Nintedanib in first-line recurrent or advanced cervical cancer [Paper presentation]. Int J Gynecol Cancer: first published as 10.1136/ijgc-2021-ESGO.16.

Vergote, I. B., Monk, B. J., O'Cearbhaill, R. E., Westermann, A. M., Banerjee, S., Collins, D. C., Mirza, M. R., O'Malley, D., GENNIGENS, C., Pignata, S., Melichar, B., Sadozye, Forget, F., Tewari, K. S., Gort, E., Soumaoro, I., Mondrup Andreassen, C., Nicacio, L. V., Van Nieuwenhuysen, E., & Lorusso, D. (19 September 2021). Tisotumab Vedotin + Carboplatin in First-Line or + Pembrolizumab in Previously Treated Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205 [Poster presentation]. Mini oral session - Gynaecological cancers.

Monk, B., Van Gorp, T., Lorusso, D., O'Cearbhaill, R., Westermann, A., Banerjee, S., Collins, D., Klat, J., Madsen, K., Baurain, J., Jackson, A., Boere, I., Pignata, S., Gort, E., Moroney, J., Soumaoro, I., Mondrup Andreassen, C., Nicacio, L., GENNIGENS, C., & Vergote, I. (30 August 2021). Tisotumab vedotin + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer: phase 1b/2 ENGOT-Cx8/GOG-3024/innovaTV 205 study dose-escalation results [Poster presentation]. 2021 IGCS Annual Global Meeting; August 30-September 2, 2021; virtual. Plenary 5.

Coleman, R., Lorusso, D., GENNIGENS, C., Gonzalez-Martin, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Vindelov, S., Chen, M., Harris, J., Smith, M., Nicacio, L., Teng, M., Laenen, A., Rangwala, R., ... Vergote, I. (May 2021). Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology, 22 (5), 609-619. doi:10.1016/S1470-2045(21)00056-5
Peer Reviewed verified by ORBi

Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., Kozlov, V., Alyasova, A., Hong, S.-H., Kapoor, A., Alonso Gordoa, T., Merchan, J. R., Winquist, E., Maroto, P., Goh, J. C., ... Gennigens, C. (Other coll.). (08 April 2021). Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 384 (14), 1289 - 1300. doi:10.1056/NEJMoa2035716
Peer Reviewed verified by ORBi

LAPAILLE, L., DE CUYPERE, M., GOFFIN, F., KAKKOS, A., GONNE, E., HERMESSE, J., LOVINFOSSE, P., DELBECQUE, K., THILLE, A., Kridelka, F., & GENNIGENS, C. (2021). Cancer du col utérin localement avancé : approche multidisciplinaire. Revue Médicale de Liège, 76 (5-6), 507-514.
Peer reviewed

GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., KRIDELKA, F., & JERUSALEM, G. (2021). Optimal treatment in locally advanced cervical cancer. Expert Review of Anticancer Therapy, 657-671. doi:10.1080/14737140.2021.1879646
Peer Reviewed verified by ORBi

Durieux, R., Tchana-Sato, V., LAVIGNE, J.-P., Radermecker, M., MOONEN, M., SCAGNOL, I., GENNIGENS, C., & Defraigne, J.-O. (2021). Recurrent cardiac intimal sarcoma misdiagnosed as a myxoma or malignant transformation of a cardiac myxoma? Journal of Cardiac Surgery, 36 (1), 357-362. doi:10.1111/jocs.15200
Peer Reviewed verified by ORBi

Vergote, I., Denys, H., De Grève, J., GENNIGENS, C., Van de Vijver, K., Kerger, J., Vuylsteke, P., & Baurain, J.-F. (2021). Standard of care in 2021 for patients with ovarian cancer in Belgium. Belgian Journal of Medical Oncology, 15 (6), 286-91.
Peer Reviewed verified by ORBi

Vergote, I., Concin, N., Mirza Raza, M., Andreassen Mondrup, C., Lorusso, D., GENNIGENS, C., Banerjee, S., O'Cearbhaill Eilish, R., Campos, S., Nicacio Viana, L., Eaton, L., O'Malley, D., Soumaoro, I., & Monk, B. (May 2020). Phase Ib/II trial of tisotumab vedotin+/- bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024) [Poster presentation]. ASCO, United States.

Delafontaine, B., De Backer, C., Beuselinck, B., Debruyne, P., D'Hondt, L., GENNIGENS, C., Gil, T., Vulsteke, C., Martinez-Chanza, N., Verbiest, A., Strijbos, M., Van Lancker, G., Pelgrims, G., & Rottey, S. (March 2020). An update on the management of metastatic clear-cell renal cell carcinoma: the BSMO expert panel recommendations. Belgian Journal of Medical Oncology, 14 (2).
Peer Reviewed verified by ORBi

GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., Barbeaux, A., Forget, F., KRIDELKA, F., & JERUSALEM, G. (February 2020). Impact of hemoglobin level and red blood cell transfusions in patients with locally advanced cervical cancer treated by chemoradiotherapy [Poster presentation]. 22nd Annual BSMO meeting, Gent, Belgium.

ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain.

Gennigens, C., DE CUYPERE, M., SEIDEL, L., HERMESSE, J., Barbeaux, A., Forget, F., Albert, A., Jerusalem, G., & Kridelka, F. (2020). Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. Cancer Medicine, 1-12. doi:10.1002/cam4.3465
Peer Reviewed verified by ORBi

Verjans, J., KRIDELKA, F., DE CUYPERE, M., & GENNIGENS, C. (2020). Locally advanced cervical cancer : a descriptive analysis of 20 patients with a visceral recurrence. European Gynecology and Obstetrics, 2 (4), 255-261.
Peer reviewed

Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H.-T., Machiels, J.-P., Spicer, J., Jones, R., Forster, M., Cornez, N., Gennigens, C., Johnson, M. L., Thistlethwaite, F. C., Rangwala, R. A., Ghatta, S., Windfeld, K., Harris, J. R., ... Coleman, R. L. (2020). Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. doi:10.1158/1078-0432.CCR-19-2962
Peer reviewed

LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain.

DE CUYPERE, M.* , Lovinfosse, P.* , Gennigens, C., HERMESSE, J., Rovira, R., Duch, J., GOFFIN, F., Hustinx, R., & Kridelka, F. (2020). Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer. International Journal of Gynecological Cancer, 0, 1-8. doi:10.1136/ijgc-2020-001676
Peer reviewed
* These authors have contributed equally to this work.

Vergote, I., Denys, H., De Greve, J., Gennigens, C., Van De Vijver, K., Kerger, J., Vuylsteke, P., & Baurain, J. F. (2020). Treatment algorithm in patients with ovarian cancer. Facts, views & vision in ObGyn, 12 (3), 227-239.
Peer reviewed

DE CUYPERE, M., LOVINFOSSE, P., GOFFIN, F., Gennigens, C., Rovira, R., Duch, J., Fastrez, M., Gebhart, G., Squifflet, J. L., Luyckx, M., Charaf, G., Crener, K., Buxant, F., Bucella, D., Jouret, M., Hustinx, R., & Kridelka, F. (2020). Added value of para-aortic surgical staging compared to (18)F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. doi:10.1016/j.ejso.2019.11.496
Peer reviewed

DE CUYPERE, M., LOVINFOSSE, P., GOFFIN, F., SCHOENEN, S., Rovira Negre, R., Duch Renom, J., Fastrez, M., Gebhart, G., Luyckx, M., Squifflet, J.-L., Charaf, G., Krener, K., Buxant, F., Bucella, D., Jouret, M., & GENNIGENS, C. (03 November 2019). Added value of para-aortic surgical staging to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer : an ONCO-GF study [Poster presentation]. ESGO 2019 Athens: 21st European Gynaecological Oncology Congress 2019, Athens, Greece.

GENNIGENS, C., KRIDELKA, F., JERUSALEM, G., SEIDEL, L., GOFFIN, F., Barbeaux, A., Forget, F., KAKKOS, A., HERMESSE, J., GONNE, E., & DE CUYPERE, M. (2019). Lymphocytes count at diagnosis is a potential survival predictor in patients treated by chemoradiation in locally advanced cervical cancer [Poster presentation]. ESGO 2019 Athens: 21st European Gynaecological Oncology Congress 2019, Athens, Greece.

GENNIGENS, C., & JERUSALEM, G. (2019). State of the art in the treatment of soft tissue sarcomas. Belgian Journal of Medical Oncology, 13 (6), 227-233.
Peer Reviewed verified by ORBi

Concin, N., Vergote, I., Lassen, U. N., Drew, Y., Machiels, J.-P., Arkenau, H.-T., Forster, M. D., Jones, R., Johnson, M. L., Slomovitz, B. M., Spicer, J. F., Cornez, N., GENNIGENS, C., Coleman, R. L., Windfeld, K., Ghatta, S., Rangwala, R. A., & Hong, D. S. (20 October 2018). A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer : updated analysis of full cervical expansion cohort [Poster presentation]. ESMO Congress 2018, Munich, Germany.

Concin, N., Vergote, I., Dean, E., Lassen, U., Drew, Y., Machiels, J.-P., Nielsen, D., Arkenau, T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnsson, M., Cornez, N., GENNIGENS, C., Fulton, B., Rangwala, R., Coleman, R., & Hong, D. (November 2017). A phase IIa study of Tisotumab Vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer : updated safety and efficacy [Poster presentation]. ESGO European Gynaecological Oncology Congress 2017, Vienna, Austria.

FRERES, P., GENNIGENS, C., Martin, D., & Jerusalem, G. (October 2017). Leptomeningeal carcinomatosis from solid tumours : a systematic review of the literature. Belgian Journal of Medical Oncology, 11, 259-264.
Peer Reviewed verified by ORBi

KREUTZ, J., Potorac, I., LUTTERI, L., GENNIGENS, C., MARTIN, D., Daly, A., BONNEVILLE, J.-F., TSHIBANDA, L., & BECKERS, A. (2017). Adipsic diabetes insipidus revealing a bifocal intracranial germinoma. Annales d'Endocrinologie. doi:10.1016/j.ando.2016.10.005
Peer Reviewed verified by ORBi

Vergote, I., Concin, N., Dean, E., Lassen, U., De Bono, J., Drew, Y., Machiels, J., Nielsen, D., Arkenau, T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnson, M., Cornez, N., GENNIGENS, C., Fulton, B., Basse, L., Lisby, S., ... Hong, D. (2017). A phase IIA study of tisotumab vedotin (Humax - TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Annals of Oncology, 28 (suppl 5), 331.
Peer Reviewed verified by ORBi

GONNE, E., COLLIGNON, J., JERUSALEM, G., & GENNIGENS, C. (2016). Le carcinome de site primitif inconnu, une entité pas si rare. Revue Médicale de Liège, 71 (10), 449-454.
Peer reviewed

Crevecoeur, J., Jossa, V., GENNIGENS, C., Parmentier, J.-C., & Crevecoeur, A. (2015). Primary osteosarcoma of the breast : a case report. Clinical Case Reports. doi:10.1002/ccr3.450
Peer Reviewed verified by ORBi

El Ali, Z., Van Brummelen, D., Wolter, P., Rottey, S., Altintas, S., Schallier, D., Debruyne, P., GENNIGENS, C., Van Aelst, F., Sideris, S., Gil, T., Sirtaine, N., D'Hondt, L., Luyten, D., Focan, C., Matus, G., Rasschaert, M., & Pelgrims, G. (February 2015). Management and systemic treatment of clear cell metastatic renal cell carcinoma: BSMO expert panel recommendations. Belgian Journal of Medical Oncology, 9 (1).
Peer Reviewed verified by ORBi

LAKOSI, F., DE CUYPERE, M., NGUYEN, V. P., JANSEN, N., WARLIMONT, B., GULYBAN, A., GENNIGENS, C., SEIDEL, L., DELBECQUE, K., COUCKE, P., HERMESSE, J., & KRIDELKA, F. (2015). Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients : a mono-institutional experience. Acta Oncologica, 54 (9), 1558-1566. doi:10.3109/0284186X.2015.1062542
Peer Reviewed verified by ORBi

FRERES, P., GONNE, E., COLLIGNON, J., GIOT, J.-B., GENNIGENS, C., & JERUSALEM, G. (2015). Prise en charge de la neutropénie fébrile chez le patient cancéreux. Revue Médicale de Liège, 70 (4), 195-200.
Peer reviewed

VROONEN, L., Maiga, I., HAMOIR, E., LILET, H., GENNIGENS, C., & Beckers, A. (2014). Neurofibromatose et phéochromocytome métastatique. In Abstract book - Annales d'Endocrinologie : 31ème Congrès de la Société Françaose d'Endocrinologie, Lyon 5-8 novembre 2014 (pp. 474).

Doupagne, A., DE CUYPERE, M., KRIDELKA, F., GOFFIN, F., DELBECQUE, K., GENNIGENS, C., LAKOSI, F., KAKKOS, A., & HERMESSE, J. (September 2014). Parametrial boost does not replace optimal BT treatment in 102 patients with locally advanced cervical cancer (LACC) [Paper presentation]. ESGO, Torino, Italy.

BARTHELEMY, N., GENNIGENS, C., Scholtes, F., TSHIBANDA, L., OTTO, B., PIRET, P., MARTIN, D., JERUSALEM, G., & COUCKE, P. (2014). Le traitement multidisciplinaire du glioblastome. Revue Médicale de Liège, 69, 63-68.
Peer reviewed

Benoit, A., Jerusalem, G., & GENNIGENS, C. (2013). Le cas clinique du mois. Métastase musculaire en présence d'un cancer de l'ovaire. Revue Médicale de Liège, 68 (11), 557-61.
Peer reviewed

Sautois, B., & GENNIGENS, C. (2013). Actualites therapeutiques dans le traitement medical du cancer de la prostate resistant a la castration. Revue Médicale de Liège, 68 (2), 94-6.
Peer reviewed

Vergote, I. B., Garcia, A., Micha, J., Pippitt, C., Bendell, J., Spitz, D., Reed, N., Dark, G., Fracasso, P. M., Ibrahim, E. N., Armenio, V. A., Duska, L., Poole, C., GENNIGENS, C., Dirix, L. Y., Leung, A. C. F., Zhao, C., Soufi-Mahjoubi, R., & Rustin, G. (2013). Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Journal of Clinical Oncology. doi:10.1200/JCO.2012.45.1278
Peer Reviewed verified by ORBi

Marchal, N., GENNIGENS, C., & JERUSALEM, G. (November 2012). Carcinomatose péritonéale d'origine indéterminée. Revue Médicale de Liège, 67 (11), 582-586.
Peer reviewed

Duerinck, J., Clement, P., Bouttens, F., Neyns, B., D'Hondt, L., GENNIGENS, C., Staelens, Y., Joosens, E., Van Fraeyenhove, F., & Rogiers, A. (September 2012). Bevacizumab for recurrent glioblastoma, early observations on patient outcome in the belgian medical need program. Neuro-Oncology, 14 (3), 51.
Peer Reviewed verified by ORBi

van der Graaf, W., Blay, J., Chawla, S., Kim, D., Bui-Nguyen, B., Casali, P., Schöffski, P., Aglietta, M., Staddon, A., Beppu, Y., Le Cesne, A., Gelderblom, H., Judson, I., Araki, N., Ouali, M., Marreaud, S., Hodge, R., Dewji, M., Coens, C., ... GENNIGENS, C. (19 May 2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 379 (9829), 1879-1886. doi:10.1016/S0140-6736(12)60651-5
Peer Reviewed verified by ORBi

GENNIGENS, C., & JERUSALEM, G. (2012). Pazopanib (Votrient) dans le traitement du cancer du rein et des sarcomes des tissus mous. Revue Médicale de Liège, 67 (7-8), 437-42.
Peer reviewed

Grünwald, V., Karakiewicz, P. I., Bavbek, S. E., Miller, K., Machiels, J.-P., Lee, S.-H., Larkin, J., Bono, P., Rha, S. Y., Castellano, D., Blank, C. U., Knox, J. J., Hawkins, R., Anak, O., Rosamilia, M., Booth, J., Pirotta, N., Bodrogi, I., & GENNIGENS, C. (2012). An international expanded-access programme of Everolimus : Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer, 48, 324-332. doi:10.1016/j.ejca.2011.06.054
Peer Reviewed verified by ORBi

BARTHELEMY, N., JANSEN, N., GENNIGENS, C., DELGAUDINE, M., & COUCKE, P. (2012). y a-t-il une place pour la radiothérapie en fin de vie ? Revue Médicale de Liège, 67 (3), 128/132.
Peer reviewed

GENNIGENS, C., & Jerusalem, G. (2011). Trabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire. Revue Médicale de Liège, 66 (7-8), 452-5.
Peer reviewed

Collignon, J., Gennigens, C., & Jerusalem, G. (July 2010). Assessment of Response to Therapy for Bone Metastases : Is it still a challenge in oncology ? PET Clinics, 5 (3), 311-326. doi:10.1016/j.cpet.2010.05.002
Peer Reviewed verified by ORBi

Pellegrini, N., Nguyen Khac, M.-T., Racaru, T., Castronovo, C., Gennigens, C., Deprez, M., & Martin, D. (20 March 2010). Pan-spinal dissemination from a supratentorial primitive neuroectodermal tumor [Poster presentation]. Réunion annuelle de la Société Belge de Neurochirurgie, LIEGE, Belgium.

Freres, P., Collignon, J., Gennigens, C., Scagnol, I., Rorive, A., Barbeaux, A., Coucke, P., & Jerusalem, G. (March 2010). Le cancer du sein "triple négatif". Revue Médicale de Liège, 65 (3), 120-126.
Peer reviewed

Gennigens, C., Sautois, B., & Jerusalem, G. (2010). Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique. Revue Médicale de Liège, 65 (4), 212-6.
Peer reviewed

Collignon, J., Gennigens, C., Rorive, A., Coucke, P., Lifrange, E., Maweja, S., Fillet, G., & Jerusalem, G. (May 2009). ANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques. Revue Médicale de Liège, 64 (5-6), 279-83.
Peer reviewed

Gennigens, C., Kridelka, F., Jerusalem, G., & Sautois, B. (2009). Ovariumkanker : nieuwe cytotoxica en ontwikkeling van gerichte therapieën. Gunaïkeia. Koninklijke Belgische Vereniging voor Gynecologie en Verloskunde, 14 (6), 174-190.
Peer reviewed

Mievis, C., Jansen, N., Schleich, F., Gennigens, C., Rorive, A., Jerusalem, G., Fillet, G., & Sautois, B. (2009). Le cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide. Revue Médicale de Liège, 64 (4), 179-81.
Peer reviewed

GONNE, E., Collignon, J., Kurth, W., Thiry, A., Henry, F., Jerusalem, G., & Gennigens, C. (2009). Angiosarcome sur lymphoedeme chronique: un cas de syndrome de Stewart-Treves. Revue Médicale de Liège, 64 (7-8), 409-13.
Peer reviewed

PHAN BA, R., DEPRETER, M., GENNIGENS, C., LENELLE, L., PITANCE, F., MASSION, P., & CANIVET, J.-L. (2009). L'image du mois: Thrombus artériel pulmonaire proximal en échocardiographie. Revue Médicale de Liège, 64 (1), 4-5.
Peer reviewed

Gennigens, C., Collignon, J., Jerusalem, G., Rorive, A., & Sautois, B. (2009). Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites. Revue Médicale de Liège, 64 (5-6), 264-7.
Peer reviewed

Christelbach, S., Vroonen, L., MAWEJA, S., Gennigens, C., & Beckers, A. (2008). A propos d'un cas de corticosurrénalome. Médecine Clinique Endocrinologie et Diabète, 34, 52-56.

Paulus, A., Gennigens, C., Fillet, G., Loly, C., & Sautois, B. (September 2007). Traitement chimiothérapique actuel du cancer de l'ovaire. Revue Médicale de Liège, 62 (9), 539-47.
Peer reviewed

Gennigens, C., Sautois, B., Rorive, A., Fillet, G., & Jerusalem, G. (2007). Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees. Revue Médicale de Liège, 62 (5-6, May-Jun), 391-8.
Peer reviewed

Jerusalem, G., Rorive, A., Gennigens, C., Sautois, B., Mievis, C., & Fillet, G. (2007). Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles. Revue Médicale de Liège, 62 Spec No, 2-5.
Peer reviewed

Gennigens, C., Menetrier-Caux, C., & Droz, J. P. (May 2006). Insulin-like growth factor (IGF) family and prostate cancer. Critical Reviews in Oncology/Hematology, 58 (2), 124-145. doi:10.1016/j.critrevonc.2005.10.003
Peer Reviewed verified by ORBi

de Leval, L., Jardon-Jeghers, C., GENNIGENS, C., & BONIVER, J. (2006). Hodgkin's Lymphoma Presenting as a Bladder Tumour. Haematologica, 91 (3), 03.
Peer Reviewed verified by ORBi

Gennigens, C., Ray-Coquard, I., & Guastalla, J.-P. (May 2005). Cas clinique: Sarcomes utérins: À propos de 5 cas et revue de la littérature. Oncologie, 7 (4), 301 - 303. doi:10.1007/s10269-005-0228-7
Peer Reviewed verified by ORBi

Gillain, S., Gennigens, C., Sautois, B., Polus, M., Bonnet, C., Fillet, G., & Jerusalem, G. (2004). Traitement du cancer du sein chez la personne âgée. Revue Médicale Suisse, 62, 1618-21.
Peer Reviewed verified by ORBi

Frere, P., Canivet, J.-L., Gennigens, C., Rebeix, J. P., Fillet, G., & Beguin, Y. (2000). Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplantation, 26 (3), 343-5. doi:10.1038/sj.bmt.1702485
Peer Reviewed verified by ORBi

Contact ORBi